.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Heart failure treatment costs in India represent a critical barrier to effective long-term disease management. A recent nationwide study published in the journal Global Heart found that 70% of patients lack any financial protection. Consequently, families pay for almost all medical expenses from their personal savings. This growing economic burden often leads to medication non-adherence and poor health outcomes.
The research analyzed 1,859 patients across 21 tertiary hospitals between 2019 and 2022. It highlighted that patients bear over 90% of their healthcare costs directly. On average, an individual spends more than ₹1 lakh annually on treatment. Because incomes often drop after a diagnosis, these expenses quickly become unsustainable. Nearly 38% of households face catastrophic spending, leading to severe financial distress and asset liquidation.
Current insurance schemes like Ayushman Bharat primarily focus on hospitalization and acute procedures. However, heart failure is a chronic condition that requires consistent outpatient care. This includes regular follow-ups, diagnostic tests, and expensive lifelong medications. Therefore, even patients with some coverage still face high out-of-pocket bills. Furthermore, many families must borrow money or sell assets just to survive.
Clinicians emphasize that financial strain directly impacts clinical care. Doctors frequently adjust treatment plans based on what a patient can afford. As a result, patients may skip essential drugs or delay necessary check-ups. Consequently, the lack of structured financial support for outpatient services remains a major gap. Expanding insurance to cover long-term pharmacy costs is essential for patient survival.
Q1: Why are heart failure treatment costs so high in India?
Costs are high because the disease requires lifelong medication and repeated hospital visits. Most insurance plans only cover inpatient stays, leaving patients to pay for daily drugs out of pocket.
Q2: How does financial burden affect clinical outcomes?
Economic pressure leads patients to cut doses or delay follow-up tests. This results in worsening heart function and more frequent, expensive emergency hospitalizations.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A recent study shows 7 in 10 heart failure patients in India lack insurance, with 90% of treatment costs paid out-of-pocket, leading to financial distress....
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
